India’s Incipient Comparative Advantage and Trade Specialization in Pharmaceutical Sector in Comparison to ASEAN
Sumit Oberoi1★, Pooja Kansra2★ Corresponding author
- 1Symbiosis School of Economics, Symbiosis International University, Pune, INDIA.
- 2Mittal School of Business, Lovely Professional University, Jalandhar, Punjab, INDIA.
CORRESPONDENCE
Sumit Oberoi
Symbiosis School of Economics, Symbiosis International University, Pune, INDIA.
Received: 12-06-2021; Revised: 19-11-2021; Accepted: 02-04-2022.
Volume 56, Issue 3 · pp. 899–906 · PUBLISHED 2022 · DOI: 10.5530/ijper.56.3.143
ABSTRACT
Introduction: Today the whole world is looking towards the rising role of Asian nations in the world trade. Amid 48 Asian nations, India’s pharmaceutical segment observed a crucial restructuring in mounting income and occupational opportunities. Aim/ Objectives: Therefore, the present study aims at measuring comparative advantage and trade specialization between India and selected ASEAN economies at harmonized standard 4-digit level of product categorization. Materials and Methods: Statistical indexes meticulously assess the secondary data by performing revealed comparative advantage (RCA) index and Lafay index. Results: Outcomes lucidly elucidate that India embraces comparative advantage and trade-specialization for pharmaceutical sectors viz. ‘Bulk Medicines’, ‘Inputs Specific to Pharmaceutical Industry’ and ‘Medical technology equipment”. Conclusion: Thus, the results advocates that industrial progressions, technical innovation, product sophistication and commodity diversification in pharmaceutical sector is a pre-requisite for India to clinch trade superiority.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Oberoi, S., & Kansra, P. (2022). India’s Incipient Comparative Advantage and Trade Specialization in Pharmaceutical Sector in Comparison to ASEAN. Indian Journal of Pharmaceutical Education and Research, 56(3), 899–906. https://doi.org/10.5530/ijper.56.3.143
